Pall acquires U.S. biotechnology company

Pall Corporation (NYSE: PLL), a global leader in filtration, separation and purification, today announced its acquisition of MicroReactor Technologies, Inc. (MRT), a privately held U.S. biotechnology company. MRT has developed a reliable, easy-to-use and cost-effective miniature bioreactor technology platform.

“We are excited by this acquisition and the increased opportunities it presents for our biotechnology process development and laboratory programs”

The acquisition of MRT, with its patented approach to high throughput miniature bioreactor equipment and disposables, expands Pall's Total Fluid ManagementSM (TFM) capabilities in the $1 billion biopharmaceuticals process monitoring and process development market.Terms of the deal were not disclosed.

Speed to market continues to be a critical driver in the biopharmaceuticals industry. High Throughput Process Development (HTPD) is a rapidly emerging approach that enables biotech drug development activities to be accomplished much faster and with less material. Cell culture optimization, as a starting point for new biotech drug development, can greatly benefit from this approach.

Founded in 2003 in Mountain View, California, MRT quickly gained market recognition for its miniature bioreactor platform that is able to improve cell culture process development through fast and accurate assessment of bioreactor performance. Since its first product arrived on the market in 2006, MRT has developed HTPD systems that control, monitor and record key process parameters for multiple individual cell culture experiments in one test sequence.

These systems are proven to simulate the performance of stirred tank bioreactors in both cell culture and microbial fermentation from bench scale (1 to 20L) to much larger scale (up to 200,000L). The disposable bioreactor cassette has 24 individual bioreactors, each of which can be independently controlled and monitored for key parameters, including pH, dissolved oxygen, and temperature.

"We are excited by this acquisition and the increased opportunities it presents for our biotechnology process development and laboratory programs," said Eric Krasnoff, Pall Corporation Chairman and CEO. "Customers seek better tools for rapid process development and process monitoring. The addition of MRT further broadens Pall Life Sciences support of customers in this rapidly growing market. We welcome the newest members of the Pall family."

"It is exciting to join Pall and support the rapid growth in our business. More importantly, it enables our customers to exploit on a wider scale, the very significant advantages that the Micro-24 bioreactor technology is bringing to the industry," said Stephen Boyer, President of MRT. 

Citations

Please use one of the following formats to cite this article in your essay, paper or report:

  • APA

    Pall Corporation. (2019, June 18). Pall acquires U.S. biotechnology company. News-Medical. Retrieved on June 12, 2024 from https://www.news-medical.net/news/20100112/Pall-acquires-US-biotechnology-company.aspx.

  • MLA

    Pall Corporation. "Pall acquires U.S. biotechnology company". News-Medical. 12 June 2024. <https://www.news-medical.net/news/20100112/Pall-acquires-US-biotechnology-company.aspx>.

  • Chicago

    Pall Corporation. "Pall acquires U.S. biotechnology company". News-Medical. https://www.news-medical.net/news/20100112/Pall-acquires-US-biotechnology-company.aspx. (accessed June 12, 2024).

  • Harvard

    Pall Corporation. 2019. Pall acquires U.S. biotechnology company. News-Medical, viewed 12 June 2024, https://www.news-medical.net/news/20100112/Pall-acquires-US-biotechnology-company.aspx.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Pall first quarter 2013 sales decrease 3.6% to $627.6 million